School of Biomedical Sciences, University of Queensland, St Lucia, Queensland 4072, Australia.
Australian Institute for Bioengineering and Nanotechnology, University of Queensland, St Lucia, Queensland 4072, Australia.
Acta Biomater. 2016 Sep 1;41:264-72. doi: 10.1016/j.actbio.2016.05.034. Epub 2016 May 28.
Thermoplastic polyurethanes (TPUs) are widely used in biomedical applications due to their excellent biocompatibility. Their role as matrices for the delivery of small molecule therapeutics has been widely reported. However, very little is known about the release of bioactive peptides from this class of polymers. Here, we report the release of linear and cyclic peptides from TPUs with different hard and soft segments. Solvent casting of the TPU at room temperature mixed with the different peptides resulted in reproducible efflux profiles with no evidence of drug degradation. Peptide release was dependent on the size as well as the composition of the TPU. Tecoflex 80A (T80A) showed more extensive release than ElastEon 5-325, which correlated with a degree of hydration. It was also shown that the composition of the medium influenced the rate and extent of peptide efflux. Blending the different TPUs allowed for better control of peptide efflux, especially the initial burst effect. Peptide-loaded TPU prolonged the plasma levels of the anti-inflammatory cyclic peptide PMX53, which normally has a plasma half-life of less than 30min. Using a blend of T80A and E5-325, therapeutic plasma levels of PMX53 were observed up to 9days following a single intraperitoneal implantation of the drug-loaded film. PMX53 released from the blended TPUs significantly inhibited B16-F10 melanoma tumor growth in mice demonstrating its bioactivity in vivo. This study provides important findings for TPU-based therapeutic peptide delivery that could improve the pharmacological utility of peptides as therapeutics.
Therapeutic peptides can be highly specific and potent pharmacological agents, but are poorly absorbed and rapidly degraded in the body. This can be overcome by using a matrix that protects the peptide in vivo and promotes its slow release so that a therapeutic effect can be achieved over days or weeks. Thermoplastic polyurethanes are a versatile family of polymers that are biocompatible and used for medical implants. Here, the release of several peptides from a range of polyurethanes was shown to depend on the type of polymer used in the polyurethane. This is the first study to examine polyurethane blends for peptide delivery and shows that the rate and extent of peptide release can be fine-tuned using different hard and soft segment mixtures in the polymer.
热塑性聚氨酯(TPU)由于其出色的生物相容性而被广泛应用于生物医学领域。它们作为小分子治疗药物传递的基质已被广泛报道。然而,对于此类聚合物中生物活性肽的释放却知之甚少。在这里,我们报告了具有不同硬段和软段的 TPU 从小分子肽中的释放情况。室温下将 TPU 与不同的肽混合进行溶剂浇铸,可得到重现性良好的流出曲线,且没有药物降解的证据。肽的释放取决于 TPU 的大小和组成。Tecoflex 80A(T80A)的释放比 ElastEon 5-325 更广泛,这与水合程度有关。结果还表明,介质的组成也会影响肽的流出速度和程度。不同 TPU 的混合可以更好地控制肽的流出,尤其是初始突释效应。载肽 TPU 延长了抗炎环肽 PMX53 的血浆半衰期,PMX53 的正常血浆半衰期不到 30 分钟。使用 T80A 和 E5-325 的混合物,在单次腹膜内植入载药膜后,可观察到 PMX53 的治疗性血浆水平长达 9 天。从混合 TPU 释放的 PMX53 显著抑制了 B16-F10 黑色素瘤在小鼠中的肿瘤生长,证明了其在体内的生物活性。本研究为基于 TPU 的治疗性肽传递提供了重要发现,可提高肽作为治疗剂的药理学效用。
治疗性肽可以是高度特异和有效的药物,但在体内吸收不良且迅速降解。这可以通过使用一种在体内保护肽并促进其缓慢释放的基质来克服,从而使治疗效果可以持续数天或数周。热塑性聚氨酯是一种用途广泛的聚合物,具有生物相容性,用于医疗植入物。在这里,研究了一系列聚氨基甲酸酯从小分子肽中的释放情况,结果表明,所使用的聚合物类型取决于所用的聚氨酯类型。这是首次研究用于肽传递的聚氨酯混合物的研究,结果表明,通过在聚合物中使用不同的硬段和软段混合物,可以精确调整肽的释放速度和程度。